Exactech, Inc. (EXAC) Announces Conference Call and Expects to Report Revenue Growth of 26% for Q3
Exactech develops and markets orthopedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. Previous announcements had claimed earnings estimates of $0.21-$0.23 diluted earnings per share. These estimates are being revised to reflect the new estimate of approximately $0.15 diluted earnings per share. Even though there is a reduction in revenue guidance, Exactech management remains strong in their anticipation for continued company growth. Conference call for all interested investors has been set for October 29th at 10:00am EST. Exactech CEO Dr. William Petty said, “Although our domestic sales were softer than expected for the third…